@@ -22,7 +22,7 @@ Engineering in Synthetic Biology follows a ‘Design-Build-Test-Learn’ (DBTL)
<br/>
In our project, our aim was to specifically target *Escherichia coli* Nissle 1917 (EcN) to hypoxic tumor regions. Following an extensive review of the literature, we selected the endogenous hypoxia-inducible promoter pPepT from EcN (Fig. 1). This choice was informed by its proven utility in tumor-targeting EcN[$^1$].
In our project, our aim was to specifically target *Escherichia coli* Nissle 1917 (EcN) to hypoxic tumour regions. Following an extensive review of the literature, we selected the endogenous hypoxia-inducible promoter pPepT from EcN (Fig. 1). This choice was informed by its proven utility in tumour-targeting EcN[$^1$].
<br/>
...
...
@@ -73,7 +73,7 @@ We applied the same procedures to another plasmid pJUMP49-2C(sfGFP) (abbreviated
<br/>
The bacterial (EcN) culture containing the O12-pept / K12-pept plasmid was inoculated into LB (with 50 μg/ml spectinomycin) at a ratio of 1:100, then grew separately under normoxic and anaerobic conditions for 16 hours. As a blank control, EcN was inoculated into LB using the same method and grew for the same duration. OD600 and fluorescence (with 488 nm as the excitation wavelength and 520 nm as the emission wavelength) was measured using Multi-Mode Microplate Reader (Biotek).
The bacterial (EcN) culture containing the O12-pept / K12-pept plasmid was inoculated into LB (with 50 μg/ml spectinomycin) at a ratio of 1:100, then was grown separately under normoxic and anaerobic conditions for 16 hours. As a blank control, EcN was inoculated into LB using the same method and grew for the same duration. OD600 and fluorescence (with 488 nm as the excitation wavelength and 520 nm as the emission wavelength) was measured using Multi-Mode Microplate Reader (Biotek).
<br/>
...
...
@@ -392,4 +392,4 @@ Despite predominant success, there is still room for improvement in our characte
7. Liang, G.-T. *et al.* Enhanced small green fluorescent proteins as a multisensing platform for biosensor development. *Front. Bioeng. Biotechnol.***10**, (2022).
